Introduction {#sec1}
============

The Ugi four-component reaction (U-4CR) is a widely used multicomponent reaction (MCR) to provide a general route to diverse peptides, macrocycles, and other complex small molecules.^[@ref1],[@ref2]^ This reaction has emerged as a powerful synthetic method for organic and pharmaceutical targets. Among MCRs, isocyanide-based multicomponent reactions (IMCRs) play an important role in pharmaceutical and drug discovery research^[@ref3]−[@ref7]^ and provide access to more diverse, complex, and novel scaffolds including small molecules and macrocycles. Macrocycles as intermediates between small molecules and biologics are useful to target flat, large, and featureless protein--protein interfaces.^[@ref8],[@ref9]^ Artificial macrocycles promise to provide better control over synthesizability and over their physicochemical properties resulting in drug-like properties. However, there are only very few general and short synthetic routes toward macrocycles. Therefore, we report here such a general and short two-step synthesis of macrocycles using the Ugi reaction.

Macrocycles can be synthesized through MCRs by using bifunctional substrates. Failli et al. first used N,C-unprotected tri- and hexapeptides to synthesize bioactive cyclic hexapeptides.^[@ref10]^ Wessjohann et al. used homobifunctional starting materials to synthesize macrocycles using Ugi reactions.^[@ref11]^ Yudin et al. introduced formylaziridines as bifunctional Ugi starting materials to synthesize spectacular macrocycles.^[@ref12],[@ref13]^ Recently, Dömling et al. has shown the great impact of the direct use of bifunctional substrates such as α-isocyano-ω-carboxylic acids^[@ref14]^ and α-carboxylic acid-ω-amines^[@ref15]^ in macrocycle synthesis via the Ugi reaction ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Of all six possible permutations of bifunctional substrates for macrocyclizations via the Ugi reaction, three have been already realized, while the last three still deserve validation: α-isocyano-ω-carboxylic acids, α-carboxylic acid-ω-amines, α-isocyano-ω-amines, α-carboxylic acid-ω-aldehydes, α-isocyano-ω-aldehyde, and α-amino-ω-aldehydes. In light of our extended research interest in MCRs and our previous experience in the chemistry of macrocycles, herein we report the use of α-isocyano-ω-amine for the synthesis of macrocycles via the Ugi-macrocyclization reaction.

![Six theoretical possibilities for macrocycle synthesis by classical Ugi 4-CR.](jo-2017-02984a_0001){#fig1}

Results and Discussion {#sec2}
======================

The first step of our current work is an extension of our recent report on using α-isocyano-ω-amines as building blocks in the cyclization reaction.^[@ref16]^ We started our study by the synthesis of amino isocyanides via coupling of diamines with isocyanide esters under protecting group free conditions. Their synthesis and isolation is demanding due to the highly polar nature of α,ω-amino isocyanides. Therefore, various solvents such as chloroform, dichloromethane (DCM), methanol, water, tetrahydrofuran, ethanol, and trifluoroethanol were tested at room temperature ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Screening of different solvents revealed that dioxane was the best solvent for this process. Purification was performed by preparative column chromatography on silica (60--200 μm) using 1:1 dichloromethane:ethyl acetate as eluent A and ammonia in methanol 5% as eluent B in a gradient method. Under the optimized conditions, ten α-isocyano-ω-amines of different lengths were synthesized from commercially available diamines in good purity and yields, each on a gram scale ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesized α,ω-Amino Isocyanides with Corresponding Yields](jo-2017-02984a_0004){#sch1}

###### Optimization of Ugi-4CR

![](jo-2017-02984a_0007){#fx1}

  entry                               solvent (M)      time (h)   catalyst/conditions   yield (%)[c](#t1fn3){ref-type="table-fn"}
  ----------------------------------- ---------------- ---------- --------------------- -------------------------------------------
  1                                   MeOH (1.0)       12         rt                    traces
  2                                   MeOH (0.1)       12         rt                    15
  3                                   MeOH (0.01)      12         rt                    48
  4                                   TFE (0.01)       12         rt                    65
  5                                   CH~3~CN (0.01)   12         rt                    22
  6                                   THF (0.01)       12         rt                    30
  7[b](#t1fn2){ref-type="table-fn"}   MeOH (0.01)      12         ZnCl~2~               43
  8[b](#t1fn2){ref-type="table-fn"}   TFE (0.01)       12         ZnCl~2~               25
  9                                   MeOH (0.01)      24         rt                    60
  10                                  MeOH (0.01)      12         sonication            20

The reaction was carried out with *N*-(5-aminopentyl)-5-isocyanopentanamide (1.0 mmol), paraformaldehyde (1.0 mmol), and 2-phenylacetic acid (1.0 mmol).

10 mol % catalyst used.

Yield of isolated product.

In the next step, the macrocyclic ring closure was carried out by an U-4CR under optimized conditions using 1 equiv of an oxo component and an acid ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The optimization was performed by using *N*-(5-aminopentyl)-5-isocyanopentanamide, paraformaldehyde, and 2-phenylacetic acid as a model reaction. The reaction did not proceed in 1.0 M methanol solution. The same reaction was carried out in different dilutions of methanol, and it was found that a highly diluted 0.01 M equimolar mixture of reactants in methanol gives the 15-membered macrocycle **6a** in good yields (60%). Although trifluoroethanol (65% yield) was slightly superior to MeOH, we chose MeOH for further scope and limitation studies due to the higher price of TFE. Polar aprotic solvents such as THF and CH~3~CN gave the product in moderate yields of 30% and 22%, respectively, at room temperature. Next, different Lewis acids such as ZnCl~2~ in MeOH and TFE as a solvent were screened. It was found that ZnCl~2~ in MeOH affords product in good yield (43%). Under sonication conditions, however, the reaction led to low yield of the product ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![Synthesized Macrocycles with Corresponding Yields](jo-2017-02984a_0005){#sch2}

With the optimized reaction conditions in hand, the scope and limitations of the Ugi-macrocyclization reaction were further investigated by synthesizing 15 different macrocycles (12--17 membered ring size) which are shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. In this reaction, several commercially available carboxylic acids, aliphatic and aromatic aldehydes, and ketones as oxo-components assemble to afford macrocyclic derivatives in good yields of 33--74% after purification by column chromatography. With aliphatic aldehydes, product was obtained in good yields, up to 50%; however, aliphatic carboxylic acids such as isobutyric acid, butyric acid, and pivalic acid resulted in only trace amounts of product.

To investigate potential intramolecular hydrogen bonds of our compounds, a sulfur-containing macrocycle was treated with *m*-chloroperbenzoic acid (*m*CPBA) in DCM to afford sulfoxide and sulfone. As an example, the reaction of macrocycle **6m** with 1 equiv and 4 equiv of *m*CPBA in DCM afforded sulfoxide **7a** and sulfone **7b** in good yields of 65% and 77%, respectively, after 4 h. As shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}, these sulfoxide and sulfone functional groups are potentially capable to form amide--sulfoxide and amide--sulfone intramolecular hydrogen bonds leading to lower energy conformations of the corresponding macrocycles with interlocked structures which could have a significant impact on biological membrane permeability.

![Selective Oxidative Modifications of a Sulfur-Containing Macrocycle](jo-2017-02984a_0006){#sch3}

X-ray crystal structures of several macrocycles with different sizes and substituents can further provide some first insight into possible solid-state conformations ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). For instance, compound **6l** shows an intramolecular hydrogen bonding.

![X-ray crystal structure of some synthesized macrocyles.](jo-2017-02984a_0002){#fig2}

Physicochemical properties are of high importance for the development of drug-like compounds. What is the property profile of our macrocycles? To answer this question, we constructed a random virtual 1000 macrocycle library (SI). We calculated some properties of the library related to drug-likeliness including molecular weight, lipophilicity, number of hydrogen bond donors and acceptors, number of rotatable bonds, polar surface area, and moment of inertia ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Interestingly, analysis of the library shows that 21% obey the Lipinski rule of 5 (RO5). The cLogP vs MW distribution of a considerable fraction of the chemical space is favorable drug-like with an average MW and cLogP of 572 and 4.1, respectively.

![Some calculated physicochemical properties of the chemical space of macrocycles. A: cLogP over MW scatter plot, B: cLogP over MW box plot, C: Lipinski RO5 radar plot, D: compound distribution based on Lipinski RO5.](jo-2017-02984a_0003){#fig3}

Moreover, punctual analysis of 3D modeled representatives and X-ray structures underline the nonflat shapes of the medium sized rings. Overall, a considerable fraction of our macrocyclic space is predicted to have drug-like properties. This is in accordance with the recent proposal that the chemical space from 500 to 1000 Da remains virtually unexplored and represents a vast opportunity for those prepared to venture into new territories of drug discovery.^[@ref17],[@ref18]^

Conclusions {#sec3}
===========

A very mild, straightforward, two-step, rapid, and highly diverse macrocycle (12--17 membered) synthesis pathway via MCRs was introduced. In this strategy, macrocyclic ring closure was performed through Ugi-4CR to afford novel complex compounds with potentially biological and pharmaceutical importance. Moreover, our strategy will allow a unique simple route for the synthesis of nonpeptidic macrocycles. Other macrocyclic scaffolds obtained from different combinations of MCRs and their applications as inhibitors for protein--protein interactions are currently being investigated in our laboratory and will be reported shortly.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

All chemicals were purchased from commercial suppliers and used without any purification unless otherwise noted. Nuclear magnetic resonance spectra were recorded. Chemical shifts for ^1^H NMR are reported as δ values, and coupling constants are in hertz (Hz). The following abbreviations are used for spin multiplicity: s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, quin = quintet, dd = double of doublets, ddd = double of doublet of doublets, m = multiplet. Chemical shifts for ^13^C NMR reported in ppm relative to the solvent peak. Thin layer chromatography was performed on silica gel plates (0.20 mm thick, particle size 25 μm). Flash chromatography was performed using RediSep R~f~ normal-phase silica flash columns (silica gel 60 Å, 230--400 mesh). Electrospray ionization mass spectra (ESI-MS) were recorded.

### Procedure and Analytical Data for Synthesis of α-Isocyano-ω-amine {#sec4.1.1}

A round-bottom flask was charged with a magnet stirrer, the diamine (6.0 equiv), and the α-isocyano-ω-methyl ester (5.0 equiv), and 1,4-dioxane (0.1 M) was added. The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica (eluent: 0--100% AB; A 1:1 mixture of EtOAc:DCM, B: methanol, next with C: methanol containing 5% concd aq ammonia, particle size: 40--63 μm).

#### *N*-(5-Aminopentyl)-5-isocyanopentanamide **3a** {#sec4.1.1.1}

The product was obtained as an oil (55%, 0.580 g). ^1^H NMR (500 MHz, CDCl~3~) δ 6.58 (t, *J* = 5.8 Hz, 1H), 3.41--3.34 (m, 2H), 3.15 (q, *J* = 6.7 Hz, 2H), 2.65 (t, *J* = 7.1 Hz, 2H), 2.16 (t, *J* = 7.0 Hz, 2H), 1.74--1.61 (m, 4H), 1.49--1.38 (m, 4H), 1.33--1.24 (m, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 172.3, 155.6, 41.4, 39.2, 35.2, 32.1, 29.2, 28.5, 24.0, 22.5. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~11~H~22~N~3~O 212.1758; found 212.1757.

#### *N*-(3-Aminopropyl)-6-isocyanohexanamide **3b**([@ref16]) {#sec4.1.1.2}

The product was obtained as an oil (60%, 0.591 g). ^1^H NMR (500 MHz, CDCl~3~) δ 6.62 (bs, 1H), 3.42--3.36 (m, 2H), 3.36--3.29 (m, 2H), 2.77 (t, *J* = 6.4 Hz, 2H), 2.18 (t, *J* = 7.5 Hz, 2H), 1.72--1.59 (m, 6H), 1.51--1.42 (m, 2H); ^13^C NMR (126 MHz, CDCl~3~) δ 172.8, 155.6, 50.2, 41.5, 39.8, 37.7, 36.3, 32.2, 28.8, 25.9.

#### *N*-(4-Aminobutyl)-3-isocyanopropanamide **3c**([@ref16]) {#sec4.1.1.3}

The product was obtained as an oil (60%, 0.464 g). ^1^H NMR (500 MHz, CD~3~OD) δ 3.78 (t, *J* = 6.3 Hz, 2H), 3.26 (t, *J* = 6.5 Hz, 2H), 2.73 (t, *J* = 6.5 Hz,, 2H), 2.66--2.51 (m, 2H), 1.64--1.51 (m, 4H); ^13^C NMR (126 MHz, CD~3~OD) δ 171.6, 156.8, 42.0, 40.3, 39.1, 36.7, 30.3, 27.9.

#### *N*-(2-((2-Aminoethyl)thio)ethyl)-3-(1*H*-indol-3-yl)-2-isocyanopropanamide **3d**([@ref16]) {#sec4.1.1.4}

The product was obtained as an oil (49%, 0.774 g). ^1^H NMR (500 MHz, CD~3~OD) δ 7.58 (d, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.20 (s, 1H), 7.10 (t, *J* = 7.5 Hz, 1H), 7.04 (t, *J* = 7.5 Hz, 1H), 4.56 (t, *J* = 6.6 Hz, 1H), 3.40--3.35 (m, 2H), 3.32 (p, *J* = 1.6 Hz, 1H), 3.29--3.18 (m, 2H), 2.72 (t, *J* = 6.6 Hz, 2H), 2.51 (t, *J* = 6.6 Hz, 2H), 2.32 (t, *J* = 7.1 Hz, 2H); ^13^C NMR (126 MHz, methanol-*d*~4~) δ 167.1, 158.4, 136.6, 127.1, 123.9, 121.2, 118.6, 118.0, 111.0, 107.7, 58.3, 40.1, 39.1, 33.7, 29.7, 29.5.

#### *N*-(6-Aminohexyl)-2-isocyano-3-phenylpropanamide **3e**([@ref16]) {#sec4.1.1.5}

The product was obtained as an oil (56%, 0.764 g). ^1^H NMR (500 MHz, CD~3~OD) δ 7.42--7.23 (m, 5H), 3.34 (t, *J* = 1.7 Hz, 1H), 3.28--3.09 (m, 4H), 2.67 (t, *J* = 7.2 Hz, 2H), 1.57--1.41 (m, 4H), 1.40--1.31 (m, 4H); ^13^C NMR (126 MHz, CD~3~OD) δ 166.3, 158.7, 135.1, 129.1, 128.3, 127.1, 58.3, 40.9, 39.3, 38.9, 31.7, 28.7, 23.3.

#### *N*-(5-Aminopentyl)-4-isocyanobutanamide **3f** {#sec4.1.1.6}

The product was obtained as an oil (45%, 0.443 g). ^1^H NMR (500 MHz, CD~3~OD) δ 3.60--3.53 (m, 1H), 3.37--3.32 (m, 1H), 3.23 (t, *J* = 7.0 Hz, 1H), 2.99--2.90 (m, 2H), 2.39 (t, *J* = 8.4, 6.4 Hz, 1H), 2.05--1.97 (m, 2H), 1.77--1.67 (m, 2H), 1.65--1.55 (m, 2H), 1.51--1.41 (m, 2H), 1.34 (t, *J* = 7.1 Hz, 1H), 1.28 (td, *J* = 7.2, 1.7 Hz, 1H). ^13^C NMR (126 MHz, CD~3~OD) δ 172.9, 154.9, 40.6, 39.3, 38.6, 32.0, 28.5, 27.0, 25.1, 23.4. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~10~H~20~N~3~O 198.1601; found 198.1600.

#### *N*-(6-Aminohexyl)-3-isocyanopropanamide **3g** {#sec4.1.1.7}

The product was obtained as an oil (42%, 0.413 g). ^1^H NMR (500 MHz, CD~3~OD) δ 3.83--3.72 (m, 1H), 3.38 (s, 2H), 3.36--3.32 (m, 1H), 3.25 (t, *J* = 7.0 Hz, 1H), 2.67 (t, *J* = 7.1, 0.9 Hz, 2H), 2.63--2.55 (m, 1H), 1.62--1.47 (m, 4H), 1.40 (m, 4H). ^13^C NMR (126 MHz, CD~3~OD) δ 170.0, 155.2, 41.0, 40.9, 39.0, 37.6, 35.1, 32.2, 32.1, 29.0. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~10~H~20~N~3~O 198.1601; found 198.1599.

#### *N*-(2-((2-Aminoethyl)thio)ethyl)-3-isocyanopropanamide **3h** {#sec4.1.1.8}

The product was obtained as an oil (38%, 0.381 g). ^1^H NMR (500 MHz, CDCl~3~) δ 6.96 (t, *J* = 5.7 Hz, 1H), 3.73 (t, *J* = 6.7, 3.4 Hz, 2H), 3.51--3.45 (m, 2H), 2.92--2.87 (m, 2H), 2.72--2.63 (m, 4H), 2.62--2.55 (m, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 168.5, 156.8, 41.0, 39.0, 37.9, 35.9, 35.7, 31.6. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~8~H~15~N~3~OS 202.1009; found 202.1008.

#### *N*-(2-((2-Aminoethyl)thio)ethyl)-5-isocyanopentanamide **3i** {#sec4.1.1.9}

The product was obtained as an oil (57%, 0.652 g). ^1^H NMR (500 MHz, CDCl~3~) δ 6.52 (t, *J* = 5.6 Hz, 1H), 3.47--3.36 (m, 4H), 2.88 (t, *J* = 6.3 Hz, 2H), 2.71--2.58 (m, 4H), 2.23 (t, *J* = 7.0 Hz, 2H), 1.85--1.67 (m, 4H). ^13^C NMR (126 MHz, CDCl~3~) δ 172.2, 155.9, 41.4, 41.0, 38.7, 35.6, 35.2, 31.6, 28.5, 22.4. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~10~H~20~N~3~OS 230.1322; found 230.1320.

#### *N*-(6-Aminohexyl)-6-isocyanohexanamide **3j** {#sec4.1.1.10}

The product was obtained as an oil (66%, 0.788 g). ^1^H NMR (500 MHz, CDCl~3~) δ 3.42 (tt, *J* = 6.6, 1.8 Hz, 1H), 3.22 (q, *J* = 6.7 Hz, 2H), 2.93--2.80 (m, 4H), 2.23 (t, *J* = 7.4 Hz, 1H), 1.76--1.58 (m, 6H), 1.57--1.44 (m, 5H), 1.43--1.35 (m, 5H). ^13^C NMR (126 MHz, CDCl~3~) δ 173.0, 155.4, 41.5, 41.1, 40.6, 39.3, 36.2, 31.3, 29.9, 28.8, 26.1, 26.0, 24.8, 24.5. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~13~H~26~N~3~O 240.2070; found 240.2069.

### Procedure and Analytical Data for the Macrocyclization Reactions {#sec4.1.2}

α-Isocyano-ω-amine (1.0 mmol) and aldehyde (1.0 mmol) were stirred at room temperature in MeOH (10 mL) for 1 h. The reaction was diluted to (0.01 M, 100 mL), and then the carboxylic acid (1.0 mmol) was added. The mixture was stirred for 24 h. The solvent was removed under reduced pressure, and the residue was purified using flash chromatography (DCM:MeOH (9:1)).

#### 4-(2-Phenylacetyl)-1,4,10-triazacyclopentadecane-2,11-dione **6a** {#sec4.1.2.1}

The product was obtained as a white solid (60%, 0.215 g, mp 164--166 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 7.66 (t, *J* = 7.0 Hz, 1H), 7.39--7.26 (m, 5H), 6.41 (t, *J* = 6.3 Hz, 1H), 3.96 (s, 2H), 3.79 (s, 2H), 3.47 (t, *J* = 6.0 Hz, 2H), 3.28 (q, *J* = 7.0 Hz, 2H), 3.18 (q, *J* = 5.6 Hz, 2H), 2.24 (t, *J* = 7.1 Hz, 2H), 1.67--1.55 (m, 4H), 1.53--1.44 (m, 4H), 1.10 (q, *J* = 7.9 Hz, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 173.5, 172.9, 170.4, 134.5, 128.8, 128.8, 127.2, 53.0, 51.8, 40.8, 38.1, 36.8, 35.2, 28.7, 27.9, 27.8, 23.4, 23.1. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~20~H~30~N~3~O~3~ 360.2282; found 360.2281.

#### 4-(2-(4-Bromophenyl)acetyl)-3-isobutyl-1,4,10-triazacyclopentadecane-2,11-dione **6b** {#sec4.1.2.2}

The product was obtained as a white solid (51%, 0.251 g, mp 170--172 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 7.44 (d, *J* = 8.3 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.59 (t, *J* = 6.1 Hz, 1H), 4.72 (s, 1H), 3.70 (d, *J* = 3.9 Hz, 2H), 3.55 (s, 1H), 3.44 (s, 1H), 3.39--3.30 (m, 2H), 3.14--2.81 (m, 2H), 2.34--2.13 (m, 2H), 1.88--1.75 (m, 1H), 1.74--1.33 (m, 10H), 1.23 (m, 2H), 0.89 (dd, *J* = 11.2, 6.6 Hz, 6H). ^13^C NMR (126 MHz, CDCl~3~) δ 173.5, 172.7, 172.1, 133.8, 131.8, 130.8, 121.1, 40.8, 40.7, 38.8, 36.9, 36.4, 35.1, 28.5, 28.0, 24.9, 24.4, 22.8, 22.7, 22.5. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~24~H~37~N~3~O~3~Br 494.2013; found 494.2011.

#### 3-(2-(Methylthio)ethyl)-4-(2-phenylacetyl)-1,4,8-triazacyclotetradecane-2,9-dione **6c** {#sec4.1.2.3}

The product was obtained as a white solid (50%, 0.209 g, mp 183--185 °C); A mixture of rotamers is observed and the major of the rotamers taken ; ^1^H NMR (500 MHz, CDCl~3~) δ 7.46--7.29 (m, 3H), 7.29--7.20 (m, 2H), 6.10 (s, 1H), 4.85 (t, *J* = 7.3 Hz, 1H), 3.77 (s, 2H), 3.73--3.54 (m, 2H), 3.53--3.37 (m, 1H), 3.35--3.20 (m, 1H), 3.18--2.96 (m, 2H), 2.57--2.34 (m, 3H), 2.34--2.21 (m, 2H), 2.12 (s, 3H), 2.08--1.92 (m, 2H), 1.86--1.58 (m, 3H), 1.45 (t, *J* = 11.1 Hz, 2H), 1.36--1.13 (m, 2H); ^13^C NMR (126 MHz, CDCl~3~) δ 173.6, 172.5, 170.7, 135.0, 129.3, 129.2, 127.5, 59.7, 53.4, 46.5, 41.9, 38.5, 37.8, 36.5, 31.2, 30.2, 29.4, 28.9, 24.2, 15.8. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~22~H~34~N~3~O~3~S 420.2315; found 420.2313.

#### 3-Isobutyl-4-(2-phenylacetyl)-1,4,8-triazacyclotetradecane-2,9-dione **6d** {#sec4.1.2.4}

The product was obtained as brown oil (74%, 0.296 g); ^1^H NMR (500 MHz, CDCl~3~) δ 7.42--7.37 (m, 2H), 7.36--7.31 (m, 3H), 6.32 (dd, *J* = 15.3, 8.5 Hz, 1H), 5.69 (t, *J* = 6.1 Hz, 1H), 5.24--5.17 (m, 1H), 3.73 (s, 2H), 3.33--3.24 (m, 4H), 3.13--3.02 (m, 2H), 2.18 (t, *J* = 7.5, 1.9 Hz, 2H), 1.71 (dd, *J* = 7.2, 5.8 Hz, 2H), 1.66--1.59 (m, 5H), 1.35--1.27 (m, 2H), 1.27--1.19 (m, 2H), 0.92 (dd, *J* = 8.2, 6.3 Hz, 6H).; ^13^C NMR (126 MHz, CDCl~3~) δ 173.6, 170.9, 170.3, 133.6, 129.2, 128.9, 127.6, 73.0, 41.6, 40.8, 38.8, 36.4, 36.0, 35.8, 29.7, 28.9, 26.2, 25.1, 24.5, 23.1, 21.7. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~23~H~36~N~3~O~3~ 402.2751; found 402.2750.

#### 2-(*tert*-Butyl)-1-(2-(4-nitrophenyl)acetyl)-1,4,8-triazacyclododecane-3,7-dione **6e** {#sec4.1.2.5}

The product was obtained as a white solid (36%, 0.150 g, mp 188--190 °C); ^1^H NMR (500 MHz, DMSO-*d*~6~) δ 8.29 (d, *J* = 8.2 Hz, 1H), 8.21--8.16 (m, 2H), 7.56--7.52 (m, 2H), 4.67 (s, 1H), 4.21--3.97 (m, 2H), 3.85--3.67 (m, 2H), 3.56 (dd, *J* = 15.2, 8.4 Hz, 1H), 3.18--2.93 (m, 2H), 2.85 (d, *J* = 13.4 Hz, 1H), 2.38--2.26 (m, 1H), 2.26--2.11 (m, 1H), 1.80--1.64 (m, 1H), 1.50--1.35 (m, 1H), 1.35--1.17 (m, 1H), 1.12 (d, *J* = 18.4 Hz, 1H), 1.10--1.02 (m, 1H), 0.89 (s, 9H). ^13^C NMR (126 MHz, DMSO-*d*~6~) δ 171.2, 171.0, 169.9, 146.7, 145.2, 131.5, 123.6, 37.9, 37.4, 37.3, 37.0, 36.9, 35.9, 28.2, 27.8, 27.1, 26.7. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~21~H~31~N~4~O~5~ 419.2289; found 419.2287.

#### 2-(4-Chlorophenyl)-1-(2-phenylacetyl)-1,4,8-triazacyclododecane-3,7-dione **6f** {#sec4.1.2.6}

The product was obtained as a yellow oil (42%, 0.179 g); ^1^H NMR (500 MHz, CDCl~3~) δ 8.66 (t, *J* = 5.2 Hz, 1H), 7.39--7.31 (m, 3H), 7.31--7.25 (m, 2H), 7.24--7.17 (m, 2H), 7.17--7.04 (m, 1H), 6.37 (t, *J* = 6.6 Hz, 1H), 3.77 (s, 2H), 3.55--3.39 (m, 4H), 3.28--3.07 (m, 2H), 2.69--2.52 (m, 2H), 1.47 (q, *J* = 3.6 Hz, 4H). ^13^C NMR (126 MHz, CDCl~3~) δ 177.6, 174.9, 171.9, 134.9, 129.3, 128.8, 128.7, 128.5, 127.0, 63.5, 45.9, 44.2, 38.8, 38.1, 35.4, 26.4, 26.1, 25.3. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~23~H~27~N~3~O~3~Cl 428.1735; found 428.1734.

#### 14-((1*H*-Indol-3-yl)methyl)-6-(2-phenylacetyl)-9-thia-6,12,15-triazaspiro\[4.11\]hexadecane-13,16-dione **6g** {#sec4.1.2.7}

The product was obtained as a yellow solid (53%, 0.274 g, mp 180--182 °C);^1^H NMR (500 MHz, CDCl~3~) δ 8.84 (d, *J* = 7.3 Hz, 1H), 8.18 (s, 1H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.36 (s, 1H), 7.34 (d, *J* = 7.4 Hz, 2H), 7.29 (d, *J* = 2.6 Hz, 1H), 7.18 (t, *J* = 7.4 Hz, 3H), 7.15--7.10 (m, 2H), 6.79 (t, *J* = 6.0 Hz, 1H), 4.67--4.55 (m, 1H), 3.88 (s, 2H), 3.68 (s, 1H), 3.61--3.56 (m, 2H), 3.45 (dd, *J* = 15.0, 5.4 Hz, 1H), 3.24 (dd, *J* = 15.0, 8.9 Hz, 1H), 3.06--2.98 (m, 2H), 2.90--2.79 (m, 1H), 2.74--2.61 (m, 1H), 2.56--2.45 (m, 1H), 2.32--2.18 (m, 1H), 1.87--1.77 (m, 1H), 1.58--1.47 (m, 4H), 1.34--1.26 (m, 1H), 1.25--1.15 (m, 1H). ^13^C NMR (126 MHz, CDCl~3~) δ 175.4, 173.8, 171.8, 136.3, 134.9, 129.4, 128.8, 128.7, 128.6, 127.3, 127.0, 123.2, 122.0, 119.4, 118.9, 111.1, 72.2, 54.9, 45.7, 43.7, 37.6, 37.2, 36.0, 35.5, 34.7, 26.2, 21.6, 21.0. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~29~H~35~N~4~O~3~S 519.2424; found 519.2424.

#### 3-Benzyl-6-(*tert*-butyl)-7-(2-phenylacetyl)-1,4,7-triazacyclotridecane-2,5-dione **6h** {#sec4.1.2.8}

The product was obtained as a white oil (33%, 0.157 g); ^1^H NMR (500 MHz, CDCl~3~) δ 7.45--7.33 (m, 5H), 7.34--7.21 (m, 3H), 4.75 (s, 1H), 3.99 (s, 2H), 3.68 (d, *J* = 5.2 Hz, 4H), 3.38 (s, 1H), 3.20--3.08 (m, 2H), 1.63--1.49 (m, 3H), 1.46--1.39 (m, 2H), 1.28 (d, *J* = 2.9 Hz, 1H), 1.24--1.20 (m, 3H), 1.15--1.09 (m, 4H), 1.07 (s, 9H). ^13^C NMR (126 MHz, CDCl~3~) δ 190.3, 183.6, 134.0, 129.0, 128.7, 127.6, 70.2, 52.0, 47.0, 40.7, 36.4, 35.7, 29.8, 28.6, 26.5, 26.4, 26.2, 26.2. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~29~H~40~N~3~O~3~ 478.2912; found 478.2912.

#### 2-Isobutyl-1-(2-phenylacetyl)-1,4,9-triazacyclotetradecane-3,8-dione **6i** {#sec4.1.2.9}

The product was obtained as a yellow oil (45%, 0.180 g); ^1^H NMR (500 MHz, CDCl~3~) δ 7.39--7.32 (m, 5H), 7.18 (d, *J* = 5.9 Hz, 1H), 5.56 (t, *J* = 6.4 Hz, 1H), 4.26 (s, 1H), 3.83 (d, *J* = 5.9 Hz, 2H), 3.62--3.54 (m, 2H), 3.32 (q, *J* = 5.3 Hz, 2H), 3.18--3.11 (m, 1H), 3.07--2.99 (m, 1H), 2.43--2.34 (m, 1H), 2.26--2.19 (m, 1H), 2.15--2.08 (m, 1H), 1.87 (t, *J* = 7.2 Hz, 2H), 1.81--1.74 (m, 1H), 1.53--1.48 (m, 2H), 1.46--1.42 (m, 1H), 1.37--1.32 (m, 1H), 1.29--1.26 (m, 1H), 1.23 (d, *J* = 6.0 Hz, 1H), 1.01 (t, *J* = 6.5 Hz, 1H), 0.90 (d, *J* = 6.2 Hz, 6H). ^13^C NMR (126 MHz, CDCl~3~) δ 173.2, 172.8, 172.4, 134.9, 128.9, 128.7, 127.0, 61.1, 48.9, 41.5, 40.7, 37.5, 37.2, 35.2, 29.1, 28.6, 25.0, 23.8, 23.1, 23.0, 22.1. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~23~H~36~N~3~O~3~ 402.2751; found 402.2750.

#### 2-(4-Isopropylphenyl)-1-(2-phenylacetyl)-1,4,8-triazacyclotetradecane-3,7-dione **6j** {#sec4.1.2.10}

The product was obtained as a white solid (39%, 0.180 g, mp 166--168 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 7.40--7.29 (m, 3H), 7.28 (s, 1H), 7.24--7.12 (m, 5H), 6.65 (s, 1H), 5.60 (s, 1H), 3.93--3.60 (m, 4H), 3.62--3.39 (m, 3H), 3.28 (d, *J* = 51.2 Hz, 2H), 3.04--2.80 (m, 1H), 2.73--2.35 (m, 2H), 1.77--1.48 (m, 4H), 1.41 (s, 2H), 1.25 (d, *J* = 7.1 Hz, 6H), 1.23 (s, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 172.8, 171.8, 171.0, 129.8, 129.2, 129.1, 128.9, 128.1, 127.3, 127.1, 126.9, 65.7, 49.8, 42.1, 39.8, 36.8, 36.0, 34.1, 29.0, 26.8, 26.5, 25.6, 24.2. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~28~H~38~N~3~O~3~ 464.2908; found 464.2906.

#### 1-(3-Phenylpropanoyl)-1,4,8-triazacyclotetradecane-3,7-dione **6k** {#sec4.1.2.11}

The product was obtained as a white solid (44%, 0.157 g, mp 177--179 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 7.34 (t, *J* = 7.5 Hz, 2H), 7.25 (q, *J* = 9.3, 7.9 Hz, 3H), 6.39 (t, *J* = 5.9 Hz, 1H), 4.01 (s, 2H), 3.54 (q, *J* = 5.9 Hz, 2H), 3.39--3.29 (m, 4H), 3.02 (t, *J* = 7.8 Hz, 2H), 2.71 (t, *J* = 7.9 Hz, 2H), 2.50 (t, *J* = 5.8 Hz, 2H), 1.63--1.51 (m, 4H), 1.44--1.36 (m, 2H), 1.28--1.20 (m, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 173.8, 170.9, 170.6, 141.0, 128.6, 128.5, 126.3, 52.3, 50.6, 39.3, 36.3, 35.6, 35.3, 31.2, 28.4, 26.7, 26.3, 25.5. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~20~H~30~N~3~O~3~ 360.2282; found 360.2279.

#### 4-(2-Phenylacetyl)-1-thia-4,7,11-triazacyclotridecane-6,10-dione **6l** {#sec4.1.2.12}

The product was obtained as a white solid (62%, 0.216 g, mp 173--174 °C); ^1^H NMR (500 MHz, DMSO-*d*~6~) δ 8.53--8.43 (m, 1H), 8.42 (d, *J* = 6.1 Hz, 1H), 7.35--7.26 (m, 2H), 7.27--7.18 (m, 3H), 3.98 (s, 2H), 3.81 (s, 2H), 3.36--3.25 (m, 6H), 2.69 (m, 2H), 2.63--2.58 (m, 2H), 2.41 (t, *J* = 5.8 Hz, 2H). ^13^C NMR (126 MHz, DMSO-*d*~6~) δ 171.6, 170.9, 169.7, 136.5, 129.8, 128.6, 126.7, 52.4, 48.6, 42.6, 40.6, 36.2, 34.5, 30.8, 29.8. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~17~H~24~N~3~O~3~S 350.1533; found 350.1532.

#### 4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentadecane-6,12-dione **6m** {#sec4.1.2.13}

The product was obtained as a white solid (58%, 0.264 g, mp 196--198 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 7.48--7.44 (m, 2H), 7.44--7.40 (m, 1H), 7.19--7.13 (m, 2H), 7.11 (d, *J* = 8.2 Hz, 2H), 3.98 (s, 2H), 3.77 (s, 2H), 3.67 (t, *J* = 6.2 Hz, 2H), 3.57 (d, *J* = 3.4 Hz, 1H), 3.46--3.37 (m, 2H), 3.33--3.22 (m, 2H), 2.90 (t, *J* = 6.2 Hz, 2H), 2.83--2.75 (m, 2H), 2.29 (t, *J* = 6.3 Hz, 2H), 1.67--1.57 (m, *J* = 5.7, 4.8 Hz, 4H). ^13^C NMR (126 MHz, CDCl~3~) δ 174.3, 172.3, 170.4, 133.3, 131.9, 130.8, 121.3, 53.1, 50.1, 40.0, 37.9, 36.7, 34.4, 31.4, 30.4, 27.8, 22.5. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~19~H~27~N~3~O~3~SBr 456.0949; found 456.0949.

#### 6-(2-(*p*-Tolyl)acetyl)-9-thia-6,12,18-triazaspiro\[4.14\]nonadecane-13,19-dione **6n** {#sec4.1.2.14}

The product was obtained as a yellow solid (69%, 0.307 g, mp 195--197 °C); ^1^H NMR (500 MHz, CDCl~3~) δ 8.16 (s, 1H), 7.12 (s, 4H), 6.66 (s, 1H), 3.76 (s, 2H), 3.67--3.56 (m, 2H), 3.48--3.36 (m, 2H), 3.32--3.18 (m, 2H), 2.79--2.61 (m, 6H), 2.31 (s, 3H), 2.21 (t, *J* = 7.2 Hz, 2H), 1.87--1.71 (m, 2H), 1.71--1.55 (m, 6H), 1.49 (dd, *J* = 7.8, 5.7 Hz, 2H). ^13^C NMR (126 MHz, CDCl~3~) δ 174.0, 173.3, 136.6, 131.5, 129.3, 128.5, 72.5, 45.9, 42.6, 39.9, 37.1, 36.0, 34.8, 31.9, 27.8, 22.5, 21.7, 20.9. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~24~H~36~N~3~O~3~S 446.2472; found 446.2471.

#### 4-(2-(4-Bromophenyl)acetyl)-3-(2-(methylthio)ethyl)-1,4,11-triazacycloheptadecane-2,12-dione **6o** {#sec4.1.2.15}

The product was obtained as a yellow oil (34%, 0.183 g). A mixture of rotamers was observed, and the major rotamer analyzed: ^1^H NMR (500 MHz, CDCl~3~) δ 7.53 (t, *J* = 8.8 Hz, 2H), 7.27 (dd, *J* = 7.9, 5.1 Hz, 2H), 7.20 (d, *J* = 8.2 Hz, 1H), 6.25 (s, 1H), 5.49 (t, *J* = 6.2 Hz, 1H), 4.96 (s, 1H), 3.85--3.77 (m, 1H), 3.73 (d, *J* = 15.1 Hz, 1H), 3.54--3.46 (m, 1H), 3.42--3.34 (m, 1H), 3.22--3.10 (m, 1H), 3.08--2.90 (m, 2H), 2.66--2.53 (m, 1H), 2.51--2.41 (m, 2H), 2.41--2.27 (m, 1H), 2.10 (s, 3H), 2.02--1.89 (m, 1H), 1.84--1.71 (m, 3H), 1.60--1.43 (m, 7H), 1.41--1.23 (m, 7H).^13^C NMR (126 MHz, CDCl~3~) δ 173.0, 172.6, 171.1, 133.8, 131.9, 131.0, 121.1, 59.6, 46.5, 40.3, 39.4, 37.7, 36.2, 30.8, 29.7, 29.7, 28.8, 27.8, 26.7, 25.6, 25.0, 24.2, 15.4. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~25~H~39~N~3~O~3~SBr 540.1890; found 540.1890.

### General Procedure and Analytical Data for the Synthesis of Sulfoxide Macrocycle {#sec4.1.3}

Macrocycle **6q** (1.0 mmol) was dissolved in 1 mL of DCM, and *m*-chloroperoxybenzoic acid (1 equiv) was added. The solution stirred at room temperature for 4 h. After completion of the reaction, the solvent was removed under reduced pressure and the residue was purified using flash chromatography (DCM:MeOH (9:1)).

#### 4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentadecane-6,12-dione 1-Oxide **7a** {#sec4.1.3.1}

The product was obtained as a white solid (65%, 0.264 g, mp 205--207 °C); ^1^H NMR (500 MHz, methanol-*d*~4~) δ 7.36 (dd, J = 17.7, 8.0 Hz, 2H), 7.13 (d, J = 8.1 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 5.27--5.23 (m, 4H), 5.17 (s, 2H), 3.82 (s, 1H), 3.74 (s, 1H), 3.50 (d, J = 8.8 Hz, 2H), 3.23--3.14 (m, 5H), 2.18--2.05 (m, 2H), 1.59--1.33 (m, 4H). ^13^C NMR (126 MHz, methanol-*d*~4~) δ 173.1, 172.0, 168.6, 134.6, 133.2, 130.0, 126.6, 125.4, 118.8, 61.2, 54.5, 51.8, 51.7, 35.7, 35.4, 26.0, 22.0, 17.6. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~19~H~27~N~3~O~4~SBr 472.0900; found 472.0901.

### General Procedure and Analytical Data for the Synthesis of Sulfone Macrocycle {#sec4.1.4}

Macrocycle **6q** (1.0 mmol) was dissolved in 1 mL of DCM, and *m*-chloroperoxybenzoic acid (4 equiv) was added. The solution stirred at room temperature for 4 h. After completion of the reaction, the solvent was removed under reduced pressure and the residue was purified using flash chromatography (DCM:MeOH (9:1)).

#### 4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentadecane-6,12-dione 1,1-Dioxide **7b** {#sec4.1.4.1}

The product was obtained as a white solid (77%, 0.375 g, mp 211--212 °C); ^1^H NMR (500 MHz, DMSO-*d*~6~) δ 7.81 (d, J = 17.2 Hz, 1H), 7.65 (s, 1H), 7.35 (dd, J = 16.2, 7.9 Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 3.99 (d, J = 22.7 Hz, 2H), 3.86--3.72 (m, 2H), 3.54 (d, J = 14.6 Hz, 3H), 3.38 (t, J = 7.6 Hz, 1H), 3.30 (d, J = 7.7 Hz, 1H), 3.27--3.09 (m, 5H), 2.57--2.51 (m, 1H), 2.12 (d, J = 7.3 Hz, 2H), 1.63--1.37 (m, 4H). ^13^C NMR (126 MHz, DMSO-*d*~6~) δ 174.6, 172.5, 169.7, 140.1, 132.4, 132.1, 132.0, 125.0, 55.2, 54.9, 53.2, 52.9, 43.1, 40.6, 38.6, 36.0, 34.8, 29.4, 23.8. HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ Calcd for C~19~H~27~N~3~O~5~SBr 488.0849; found 488.0848.
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